Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967458 | 1.00 | BTK (0.40) | BTKROCK2MGLLTGFBR1MAP3K5 | |
| SCHEMBL23389852 | 0.87 | LRRK2 (0.39) | TGFBR1 | |
| SCHEMBL25822669 | 0.86 | BTK (0.42) | BTKROCK2MGLLTGFBR1MAP3K5 | |
| SCHEMBL29967907 | 0.78 | LRRK2 (0.37) | TGFBR1 | |
| SCHEMBL23418646 | 0.78 | LRRK2 (0.37) | TGFBR1 | |
| SCHEMBL23389863 | 0.77 | LRRK2 (0.38) | TGFBR1 | |
| SCHEMBL28785430 | 0.75 | TGFBR1 (0.41) | TGFBR1 | |
| SCHEMBL29967757 | 0.74 | TGFBR1 (0.39) | BTKTGFBR1MAP3K5BLK | |
| SCHEMBL25822670 | 0.74 | TGFBR1 (0.39) | BTKTGFBR1MAP3K5BLK | |
| SCHEMBL23392193 | 0.73 | TGFBR1 (0.40) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | BTK 1305/4885ROCK2 631/4885MGLL 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.